Intermittent/cyclic etidronate 400 mg/day vs placebo
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes onlyRR 1.41 [0.81, 2.47]Studies not reportedLow